Table 1 |
|||
|
Summary of country of origin, number of cases included, 18S NASBA positive cases and gametocyte carriers |
|||
|
Country |
Total number of cases included in the study |
Total number of 18S NASBA positive cases from the respective country |
Gametocyte carriers as assessed by Pfs25 NASBA |
|
|
|||
|
Ivory Coast – West Africa |
14 |
3 |
1 |
|
Togo – West Africa |
3 |
||
|
Guinea – West Africa |
8 |
2 |
|
|
Somalia – East Africa |
37 |
11 |
1 |
|
Ethiopia – East Africa |
1 |
||
|
Eritrea – East Africa |
63 |
18 |
2 |
|
Ghana – West Africa |
20 |
6 |
3 |
|
Nigeria – Central Africa |
17 |
8 |
1 |
|
Burkina Faso – West Africa |
7 |
1 |
1 |
|
Mali – West Africa |
9 |
6 |
3 |
|
Cameroon – Central Africa |
1 |
||
|
Liberia – West Africa |
3 |
2 |
1 |
|
Gambia – West Africa |
4 |
1 |
|
|
Chad – Central Africa |
2 |
||
|
Senegal – West Africa |
2 |
1 |
|
|
Sudan – East Africa |
3 |
2 |
|
|
Congo – Central Africa |
1 |
1 |
|
|
|
|||
|
Total |
195 |
62 |
13 |
|
|
|||
|
Marangi et al. Malaria Journal 2009 8:12 doi:10.1186/1475-2875-8-12 |
|||